Umeclidinium

Drug Profile

Umeclidinium

Alternative Names: 573719; Ellipta Incruse; Encruse Ellipta; GSK-573719; Incruse; Incruse Ellipta; UMEC; Umeclidinium bromide

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator GlaxoSmithKline
  • Class Benzhydryl compounds; Bronchodilators; Quinuclidines; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Chronic obstructive pulmonary disease
  • Phase II Asthma; Hyperhidrosis

Most Recent Events

  • 17 Feb 2017 Umeclidinium is still in phase II trials for Asthma in USA (NCT01573624) (NCT01641692)
  • 17 Feb 2017 No development reported - Phase-II for Asthma (Monotherapy) in Bulgaria, Germany, Mexico, Peru, Poland (Inhalation)
  • 26 Jan 2017 Committee for Medicinal Products for Human Use (CHMP) recommends granting marketing authorisation for Rolufta for maintenance bronchodilator treatment for Chronic obstructive pulmonary disease
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top